An interventional study of Multimodal Lifestyle Intervention and Lifestyle Recommendations and Counseling in Subjective Cognitive Decline (SCD), sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation. Recruiting at 1 site in Spain. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation — 5 open to participants now, 7 under way, none of them phase 3. Alzheimer Disease · Barcelonabeta Brain Research Center, Pasqual Maragall Foundation.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, this one is one of 3 that started in 2026, is one of 6 with no phase, and was the 14th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →5 of the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation are open now, in 1 country. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 45+ · Healthy volunteers
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 45–75 · Healthy volunteers
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 60+
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 50–75 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 120 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 176 across the 6 interventional studies, 250 across the 9 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation is the lead sponsor of 22 studies on the registry; 7 are open to participants now.
4 of the studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02685969Barcelonabeta Brain Research Center, Pasqual Maragall FoundationBrain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants | 2026-12-31 |
| NCT03851523Barcelonabeta Brain Research Center, Pasqual Maragall FoundationLongitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease. | 2026-12-31 |
| NCT07521722Barcelonabeta Brain Research Center, Pasqual Maragall FoundationDIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community | 2027-04-27 |
| NCT07730671Barcelonabeta Brain Research Center, Pasqual Maragall FoundationPENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Alzheimer Disease by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the feasibility of implementing a Brain Health Service (BHS) to assess and reduce dementia risk in individuals with Subjective Cognitive Decline (SCD). A total of 120 participants will be recruited from the Cognitive Disorders Unit at Hospital del Mar and randomly assigned to either a personalized intervention group or a control group receiving general prevention advice.
The study will assess individual biological and lifestyle-related risk factors for dementia and use validated tools to estimate each participant's risk profile. Participants in the intervention group will be offered a structured dementia risk communication and counseling process, with the option to receive or decline their individual risk estimate.
The intervention consists of a 6-month multimodal program combining digital and in-person strategies tailored to each participant's risk level. These strategies include personalized recommendations to improve lifestyle factors such as diet, physical activity, sleep, social engagement, and cognitive stimulation.
The main objectives are to evaluate the feasibility of delivering this type of service, including recruitment, adherence, and retention; to assess the psychological impact of communicating dementia risk; and to examine changes in lifestyle behaviors and cognitive outcomes over time compared with a control group.
This study addresses the need for early, personalized prevention strategies for individuals with SCD and may inform broader implementation of preventive BHS.
The scientific literature highlights the potential of dementia prevention, with studies showing decreasing incidence rates in developed countries and clinical trials demonstrating the benefits of multimodal lifestyle interventions. However, translating this evidence into clinical practice requires further scientific validation.
Subjective Cognitive Decline (SCD) refers to individuals who report cognitive complaints despite normal performance on standardized cognitive tests. This population is increasingly represented in memory clinics, accounting for approximately 20-30% of consultations in some European centers. Individuals with SCD have an increased risk of developing mild cognitive impairment and dementia compared with those without cognitive complaints, and SCD may represent an early clinical manifestation of neurodegenerative disease. However, current clinical pathways are primarily oriented toward diagnosis and management of established impairment, and individuals with SCD are often discharged without access to personalized risk assessment or prevention strategies.
Brain Health Services (BHS) have been proposed as a new clinical model to address this gap. These services aim to provide comprehensive dementia risk assessment, individualized risk communication, and tailored prevention strategies. Core components include the evaluation of modifiable and biological risk factors, the use of validated algorithms for risk stratification, structured and ethically sound risk communication, and personalized interventions targeting multiple domains of brain health.
The B-HEALTH project is a proof-of-concept longitudinal study designed to evaluate the feasibility and preliminary impact of implementing a Brain Health Service in a real-world clinical setting. A total of 120 participants with SCD will be recruited from the Cognitive Disorders Unit at Hospital del Mar and randomly assigned to either an intervention group or a control group receiving general dementia prevention advice.
Participants will undergo a comprehensive risk assessment integrating clinical, lifestyle, and biological information. Individual dementia risk profiles will be generated using validated risk scores (e.g., LIBRA index) and blood-based markers of Alzheimer's Disease (AD) pathology (ptau-217). Participants in the intervention group will be offered a structured Dementia Risk Communication and Counseling process and may choose whether or not to receive their individualized risk estimate.
Following this, participants in the intervention group will receive a 6-month multimodal prevention program tailored to their level of dementia risk. The intervention targets physical activity, nutrition, sleep, cognitive stimulation, psychoeducation, and social engagement. The intensity of the intervention will be adapted according to individual risk level.
The program combines digital health (eHealth) tools with in-person components. These include a mobile application and a fitness tracker for continuous monitoring and feedback on lifestyle behaviours and sleep, digital cognitive assessments, and computerized cognitive training.
The primary objective of the study is to evaluate the feasibility of implementing this personalized risk stratification and prevention model in a clinical setting, including recruitment, adherence, and retention. Secondary objectives include assessing the psychological impact and acceptability of dementia risk communication, and exploring the effects of the multimodal intervention on lifestyle behaviors and cognitive outcomes. Additional exploratory analyses will examine associations between modifiable and biological risk factors and longitudinal cognitive performance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the control arm will receive general recommendations on dementia risk reduction at the beginning of the study, reflecting standard preventive advice. They will have access to a mobile application providing information on dementia risk factors; however, the application will not include personalized feedback or interactive intervention components. Participants will also be provided with a wearable fitness tracker to support monitoring of physical activity and sleep.
Behavioral: Lifestyle Recommendations and Counseling
Participants in the experimental arm will receive a 6-month personalized, multimodal intervention tailored to their individual dementia risk profile. The intervention includes components targeting key domains of brain health, including nutrition, physical activity, cognitive training, and psychoeducation, with the intensity and combination of components adapted according to risk level. Participants will have access to a mobile application providing personalized feedback on lifestyle behaviors and interactive support to promote adherence to the intervention. Participants will also be provided with a wearable fitness tracker to support monitoring of physical activity and sleep.
Behavioral: Multimodal Lifestyle Intervention
The intervention is a 6-month personalized, multimodal dementia risk reduction program based on individual risk stratification. Risk profiles are defined using modifiable and non-modifiable risk factors for Alzheimer's disease, allowing participants to be categorized into low, intermediate, or high-risk groups. All participants in the intervention arm will receive structured and personalized counseling delivered through a mobile application. Participants in the intermediate- and high-risk groups will additionally be invited to: (i) complete individual 30-minute cognitive training sessions 2 to 3 times per week via a telematic platform, and (ii) attend monthly psychoeducational group sessions led by a psychologist or trained nurse. Participants in the high-risk group will further be invited to attend individual nutrition counseling visits (one session per month) and supervised group-based physical activity sessions in a gymnasium setting (one session per week).
Also known as: Non-pharmacological intervention
Standard recommendations on dementia risk reduction will be provided at the beginning of the study, based on general guidance for maintaining brain health. Participants will have access to a mobile application providing educational information on dementia risk factors and healthy lifestyle behaviors. The content will be static and non-interactive, without personalized feedback or tailored recommendations
Also known as: General Lifestyle Recommendations
Feasibility of the multimodal intervention
Feasibility will be assessed using recruitment, adherence, and retention rates: 1. Recruitment rate: proportion of participants randomized among those eligible and invited to participate. A rate ≥50% will be considered successful. 2. Adherence: defined as completion of at least 50% of intervention components, including ecological momentary assessments (EMAs), online questionnaires, in-person activities, and cognitive training sessions. Participants meeting this threshold will be classified as adherent. 3. Retention rate: proportion of participants who complete the 6-month intervention period. A dropout rate \<20% will be considered acceptable. Reasons for dropout will be recorded.
Time frame: 6 months
Feasibility of dementia risk communication and counseling
Feasibility will be assessed by uptake and completion rates (%) of the risk communication and counseling process.
Time frame: 6 months
Psychological impact of risk communication: post-traumatic stress symptoms
Psychological impact will be assessed using the Impact of Events Scale-Revised (IES-R). Scale ranges from 0 to 88, with a higher score indicating greater post-traumatic stress symptoms.
Time frame: 6 months
Psychological impact of risk communication: anxiety
Anxiety will be assessed using the Hospital Anxiety and Depression Scale, anxiety subscale (HADS-A). Scale ranges from 0 to 21. A score higher than 8 is taken as threshold for clinically relevant anxiety. A higher score represents a higher degree of anxiety.
Time frame: 6 months
Psychological impact of risk communication: depressive symptoms
Depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale, depression subscale (HADS-D). Scale ranges from 0 to 21. A score higher than 8 is taken as threshold for clinically relevant depressive symptoms. A higher score represents a higher degree of depression.
Time frame: 6 months
Psychological impact of risk communication: situational anxiety
Situational anxiety will be assessed using the State-Trait Anxiety Inventory, state subscale (STAI-S). Scale ranges from 20 to 80, with a higher score corresponding to a higher degree of situational anxiety.
Time frame: 6 months
Change in lifestyle-related dementia risk (LIBRA index)
Change in modifiable dementia risk factors will be assessed using a modified Lifestyle for Brain Health (LIBRA) index score based on weighted z-scores of continuous risk factor measures, which is sensitive to changes over time. The LIBRA score ranges between -5.9 and 12.7 (Schiepers et al., 2018; PMID: 28247500), with a higher score relating to a higher risk of developing dementia.
Time frame: Baseline to 6 months
Change in cognitive performance
Cognitive performance will be assessed using standardized and digital cognitive tests to evaluate changes over time between intervention and control groups.
Time frame: Baseline to 6 months
Prevalence of modifiable and biological dementia risk factors
Baseline characterization of modifiable risk factors and biological markers
Time frame: Baseline
Cognitive Performance Score as a Function of LIBRA Dementia Risk Score
Exploratory analysis of the association between LIBRA dementia risk score and cognitive performance assessed using conventional and digital cognitive tests. The association will be evaluated using regression models.
Time frame: Baseline to 6 months
Cognitive Performance Score as a Function of Plasma p-tau217 Concentration
Exploratory analysis of the association between plasma p-tau217 concentration and cognitive performance assessed using conventional and digital cognitive tests. The association will be evaluated using regression models.
Time frame: Baseline to 6 months
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 15 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation